You just read:

Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD

News provided by

Symic Biomedical

Aug 26, 2015, 09:58 ET